Our results call into question the suggestion that KRAS and BRAF mutations are always early events in the evolution of lung adenocarcinoma, consistent with the conclusion of Sugio et al that KRAS can be a late event in the pathogenesis of lung cancer [22]. This evidence concerns the gene KRAS and lung cancer.